Emory is part of a six-university consortium named
to lead a new biodefense initiative developing the next generation
of vaccines, drugs and diagnostic tests against emerging infections
such as SARS, and for defense against organisms such as smallpox
that might be used in bioterrorist attacks.
The Southeast Regional Center of Excellence for Emerging Infections
and Biodefense (SERCEB) will include researchers from Emory, Duke
University Medical Center, University of Alabama at Birmingham (UAB),
University of Florida (UF), University of North Carolina (UNC) at
Chapel Hill School of Medicine, and Vanderbilt University Medical
Center.
The consortium will be centered at Duke and led by Barton Haynes
of the Duke Human Vaccine Institute. Its co-leaders are David Stephens,
professor of medicine at Emory; UAB’s Richard Whitley; Richard
Moyer from UF; Frederick Sparling at UNC; and Vanderbilt’s
Mark Denison.
“This is an important step in defending our country against
both a wide variety of emerging infections and a potential bioterror
attack,” Haynes said. “Over the past year, we have seen
natural outbreaks of SARS, West Nile virus and monkeypox that were
not anticipated. SERCEB investigators hope to develop general strategies
that can help protect the public not only from potential bioterrorist
agents such as smallpox, plague and anthrax, but also from naturally
occurring emerging infections that so frequently jump from animals
to man.”
The National Institute of Allergy and Infectious Diseases and the
Department of Health and Human Services announced more than $45
million in funding over five years for SERCEB, one of eight “Regional
Centers of Excellence for Biodefense and Emerging Infectious Diseases
Research.”
The centers will develop programs of basic and applied research;
train researchers and other personnel for emerging infection and
biodefense research activities; and develop and maintain comprehensive
scientific core facilities to support their research and training
activities.
The Woodruff Health Sciences Center anticipates receiving approximately
$12 million over five years as part of the SERCEB funding. Research
programs at Emory will include scientists in the School of Medicine,
the Yerkes National Primate Research Center, the Emory Vaccine Center
and the Rollins School of Public Health, and collaborations with
the CDC.
SERCEB also will maintain and make available core facilities and
other support to approved investigators from academia, industry
and government agencies. These investigators will be able to perform
basic research and test and evaluate vaccines, therapeutics and
diagnostics for emerging infections and select agents.
The consortium’s initial work will focus on developing new
vaccines, diagnostics and treatments for orthopoxviruses (including
smallpox and monkeypox), Bacillus anthracis (anthrax) and Y. pestis,
the bacteria that causes plague.
Research is targeted to begin this fall at the six SERCEB member
institutions. Government partners with the SERCEB teams will include
the CDC, Oak Ridge National Laboratory and the National Institutes
of Health. In addition, research team members from the University
of Michi-gan, Southern Research Institute, Yerkes and Tulane University
Primate Center will collaborate with SERCEB investigators.
“SERCEB includes some of the most outstanding investigators
in immunology and infectious diseases in the United States,”
Haynes said. “Each member institution has enormous resources.
We believe that by working synergistically in this virtual center,
we can address difficult problems in ways we could not address them
before—and with speed that will rapidly benefit the public.
This funding will allow us to carry out unprecedented research in
a collaborative manner.”
“Emory is excited to play an important role in this new NIH-funded
regional center,” Stephens said. “The goals of SERCEB
are to develop new vaccines, drugs and diagnostics for biological
threats. Education and training in infectious diseases and biologic
threats also will be an important component of SERCEB, and Emory
will play a leadership position in this area. Emory, Atlanta and
the partners of SERCEB are uniquely positioned to contribute to
this critical national effort.”
“[Yerkes], in partnership with [Tulane], will provide a critical
component of this collaboration—that being the Nonhuman Primate
Animal Core within the regional center,” said Yerkes Director
Stuart Zola, the core’s primary investigator. “Our goal
is to provide highly integrated support, animal expertise, clinical
management, comprehensive clinical care and laboratory data using
nonhuman primate models. Our research will provide a critical step
between mouse models and clinical trials in humans.”
|